

US009272162B2

(12) United States Patent

Slayton et al.

(10) Patent No.:

US 9,272,162 B2

(45) Date of Patent:

*Mar. 1, 2016

(54) IMAGING, THERAPY, AND TEMPERATURE MONITORING ULTRASONIC METHOD

(71) Applicant: Guided Therapy Systems, LLC, Mesa,

AZ (US)

(72) Inventors: **Michael H. Slayton**, Mesa, AZ (US);

Peter G. Barthe, Phoenix, AZ (US)

(73) Assignee: GUIDED THERAPY SYSTEMS,

LLC, Mesa, AZ (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 13/937,190

(22) Filed: Jul. 8, 2013

(65) Prior Publication Data

US 2013/0296697 A1 Nov. 7, 2013

Related U.S. Application Data

(63) Continuation of application No. 11/744,655, filed on May 4, 2007, now Pat. No. 8,480,585, which is a continuation of application No. 10/193,419, filed on Jul. 10, 2002, now Pat. No. 7,229,411, which is a

(Continued)

(51) **Int. Cl.**

A61B 8/00 (2006.01) **A61N 7/02** (2006.01)

(Continued)

(52) U.S. Cl.

CPC ... *A61N 7/02* (2013.01); *A61B 5/01* (2013.01); *A61B 5/015* (2013.01); *A61B 5/4836* (2013.01);

(Continued)

(58) Field of Classification Search

CPC A61B 2017/22028; A61B 5/01; A61B 5/015; A61B 5/4836; A61B 8/0833; A61B 8/15; A61B 8/5223; A61N 7/02

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

2,427,348 A 9/1947 Bond et al. 3,913,386 A 10/1975 Saglio

(Continued)

FOREIGN PATENT DOCUMENTS

DE 4029175 3/1992 DE 10140064 3/2003

(Continued)

OTHER PUBLICATIONS

European Examination Report in related Application No. 05808908.7 dated Jun. 29, 2009.


(Continued)

Primary Examiner — Ruth S Smith (74) Attorney, Agent, or Firm — Quarles & Brady, LLP

(57) ABSTRACT

An ultrasonic system useful for providing imaging, therapy and temperature monitoring generally comprises an acoustic transducer assembly configured to enable the ultrasound system to perform the imaging, therapy and temperature monitoring functions. The acoustic transducer assembly comprises a single transducer that is operatively connected to an imaging subsystem, a therapy subsystem and a temperature monitoring subsystem. The ultrasound system may also include a display for imaging and temperature monitoring functions. Additionally, the acoustic transducer assembly can be configured to provide three-dimensional imaging, temperature monitoring or therapeutic heating through the use of adaptive algorithms and/or rotational or translational movement. Moreover, a plurality of the exemplary single transducers can be provided to facilitate enhanced treatment capabilities.

7 Claims, 15 Drawing Sheets



4,874,562 A 4,875,487 A Related U.S. Application Data 10/1989 Hyon 10/1989 Seppi continuation of application No. 08/950,353, filed on 1/1990 4,891,043 A Zeimer et al. Oct. 14, 1997, now Pat. No. 6,050,943, application No. 4.893.624 A 1/1990 Lele 4,896,673 A 1/1990 Rose 11/744,655, which is a continuation-in-part of appli-4,900,540 A 2/1990 Ryan et al. cation No. 09/502,174, filed on Feb. 10, 2000, now Pat. 4,901,729 A 2/1990 Saitoh et al. No. 6,500,121. 4,917,096 A 4/1990 Englehart 4,973,096 A 4/1990 Jaworski 4.932,414 A 6/1990 Coleman et al. (51) **Int. Cl.** 4,938,216 A 7/1990 Lele A61B 5/01 (2006.01)7/1990 4,938,217 A Lele A61B 8/08 (2006.01)4,947,046 A 8/1990 Kawabata et al. A61B 5/00 (2006.01)4,951,653 A 8/1990 Fry et al. A61B 8/15 (2006.01)4,955,365 A 9/1990 Fry et al. 4,958,626 A 9/1990 A61B 17/22 (2006.01)Nambu 4,976,709 A 12/1990 Sand (52) U.S. Cl. 4,979,501 A 12/1990 Valchanov CPC A61B 8/0833 (2013.01); A61B 8/15 4.992,989 A 2/1991 Watanabe et al. (2013.01); A61B 8/5223 (2013.01); A61B 5.012.797 A 5/1991 Liang 5.018,508 A 5/1991 Fry et al. 2017/22028 (2013.01) 7/1991 5,030,874 A Saito et al. 5,036,855 A 8/1991 Fry et al. (56)References Cited 5,040,537 A 8/1991 Katakura 5,054,310 A 10/1991 Flynn U.S. PATENT DOCUMENTS 5,054,470 A 10/1991 Fry et al. 5,070,879 A 12/1991 Herres 3,965,455 A 6/1976 Hurwitz 5,088,495 A 2/1992 Miyagawa 3,992,925 A 11/1976 Perilhou 5,115,814 A 5/1992 Griffith 4,039,312 A 8/1977 Patru 6/1992 5,117,832 A Sanghvi et al. 11/1977 4,059,098 A Murdock 6/1992 5,123,418 A Saurel 4,101,795 A 7/1978 Fukumoto 5,143,063 A 9/1992 Fellner 4,166,967 A 9/1979 Benes et al. 5,143,074 A 9/1992 Dory 4,211,948 A 7/1980 Smith et al. 5,149,319 A 9/1992 Unger 4,211,949 A 7/1980 Brisken et al. 5,150,711 A 9/1992 Dory 4,213,344 A 7/1980 Rose 5,150,714 A 9/1992 Green 4,276,491 A 6/1981 Daniel 5,152,294 A 10/1992 Mochizuki et al. 4,315,514 A 2/1982 Drewes et al. 5,156,144 A 10/1992 Iwasaki 4.325.381 A 4/1982 Glenn 10/1992 5,158,536 A Sekins 4,343,301 A 8/1982 Indech 11/1992 5.159.931 A Pini 4,372,296 A 2/1983 Fahim 5,163,421 A 11/1992 Bernstein 4,379,145 A 4/1983 Masuho et al. 5,163,436 A 11/1992 Saitoh et al. 4,381,007 A 4/1983 Doss 5,178,135 A 1/1993 Uchiyama et al. 4,381,787 A 5/1983 Hottinger 5,190,518 A 3/1993 Takasu 4,397,314 A 8/1983 Vaguine 5,190,766 A 3/1993 Ishihara 4,409,839 A 10/1983 Taenzer 5.191.880 A 3/1993 McLeod 4,431,008 A 2/1984 Wanner et al. 5,205,287 A 4/1993 Erbel et al. 4.441.486 A 4/1984 Pounds 5/1993 5,209,720 A Unger 4,452,084 A 4,484,569 A 6/1984 Taenzer 5/1993 5,212,671 A Fujii et al 11/1984 Driller et al. 5,215,680 A 6/1993 D'Arrigo 4,507,582 A 3/1985 Glenn 5,224,467 A 7/1993 Oku 4,513,749 A 4/1985 Kino 5,230,334 A 7/1993 Klopotek 4,513,750 A 4/1985 Heyman et al. 5,230,338 A 7/1993 Allen et al. 4,527,550 A 7/1985 Ruggera et al. 5,247,924 A 9/1993 Suzuki et al. 4,528,979 A 7/1985 Marchenko 5.255,681 A 10/1993 Ishimura et al. 4,534,221 A 8/1985 Fife et al. 5,257,970 A 11/1993 Dougherty 4,566,459 A 1/1986 Umemura et al. 5,265,614 A 11/1993 Hayakawa 4,567,895 A 2/1986 Putzke 12/1993 5,267,985 A Shimada et al. 4,586,512 A 5/1986 Do-huu 5,269,297 A 12/1993 Weng 4,601,296 A 7/1986 Yerushalmi 5,282,797 A 2/1994 Chess 4,620,546 A 11/1986 Aida et al. 5,295,484 A 3/1994 Marcus et al. 4,637,256 A 1/1987 Sugiyama et al. 5,295,486 A 3/1994 Wollschlager et al. 4,646,756 A 3/1987 Watmough et al. 5,304,169 A 4/1994 Sand 4,663,358 A 5/1987 Hyon 5,305,756 A 4/1994 Entrekin et al. 5/1987 4,668,516 A Duraffourd et al. 5,321,520 A 6/1994 Inga et al. 4.672.591 A 6/1987 Breimesser et al. 5,323,779 A 6/1994 Hardy et al. 4,680,499 A 7/1987 Umemura et al. 7/1994 5.327.895 A Hashimoto et al. 4,697,588 A 4,754,760 A 10/1987 Reichenberger 9/1994 5,348,016 A Unger et al. 7/1988 Fukukita et al. 5,360,268 A 11/1994 Hayashi 4,757,820 A 7/1988 Itoh 5,370,121 A 12/1994 Reichenberger et al. 4,771,205 A 9/1988 Mequio 5,371,483 A 12/1994 Bhardwaj 4,801,459 A 1/1989 Liburdy 12/1994 5.375,602 A Lancee et al. 4,803,625 A 2/1989 Fu et al. 5,379,773 A 1/1995 Hornsby 4.807.633 A 2/1989 Frv 5,380,280 A 1/1995 Peterson 4,817,615 A 4/1989 Fukukita et al. 5,380,519 A 1/1995 Schneider et al. 8/1989 Fry et al. 4,858,613 A 5,383,917 A 1/1995 Desai et al. 8/1989 4,860,732 A Hasegawa et al. 4,865,041 A 5,391,140 A 2/1995 Schaetzle et al. 9/1989 Hassler 5.391.197 A 2/1995 Burdette et al. 4,865,042 A 9/1989 Umemura 4,867,169 A 9/1989 Machida 5,392,259 A 2/1995 Bolorforosh

(56)	Referen	ices Cited	5,727,554			Kalend et al.
U.S	S. PATENT	DOCUMENTS	5,735,280 5,743,863			Sherman et al. Chapelon
· · ·	3, 11, 11, 12, 11	D 0 0 0 IIIDI (ID	5,746,005	A	5/1998	Steinberg
5,396,143 A	3/1995	Seyed-Bolorforosh et al.	5,746,762		5/1998	
5,398,689 A		Connor et al.	5,748,767		5/1998	
5,406,503 A		Williams, Jr. et al.	5,749,364			Sliwa et al.
5,417,216 A		Tanaka	5,755,228 5,755,753			Wilson et al. Knowlton
5,419,327 A		Rohwedder	5,762,066			Law et al.
5,423,220 A 5,435,311 A		Finsterwald et al. Umemura et al.	5,763,886			Schulte
5,438,998 A		Hanafy	5,769,790		6/1998	Watkins et al.
5,458,596 A	10/1995		5,779,644			Eberle et al.
5,460,179 A		Okunuki et al.	5,792,058			Lee et al.
5,460,595 A		Hall et al.	5,795,297 5,795,311		8/1998 8/1998	
5,469,854 A	11/1995	Unger et al.	5,810,009			Mine et al.
5,471,988 A 5,487,388 A		Rello et al.	5,810,888		9/1998	
5,492,126 A		Hennige et al.	5,814,599	A		Mitragotri et al.
5,496,256 A	3/1996		5,817,013			Ginn et al.
5,501,655 A		Rolt et al.	5,817,021			Reichenberger
5,503,152 A		Oakley et al.	5,820,564 5,823,962		10/1998	Schaetzle et al.
5,503,320 A 5,507,790 A		Webster et al.	5,827,204			Grandia et al.
5,520,188 A	4/1996 5/1996	Hennige et al.	5,840,032			Hatfield et al.
5,522,869 A		Burdette et al.	5,844,140	A	12/1998	Seale
5,523,058 A		Umemura et al.	5,853,367			Chalek et al.
5,524,620 A		Rosenschein	5,869,751		2/1999	
5,524,624 A		Tepper	5,871,524 5,873,902			Knowlton Sanghvi et al.
5,524,625 A		Okazaki et al.	5,876,341			Wang et al 600/441
5,526,624 A 5,526,812 A	6/1996 6/1996	Dumoulin et al.	5,876,431			Spehr et al.
5,526,814 A		Cline et al.	5,879,303	\mathbf{A}	3/1999	Averkiou et al.
5,526,815 A		Granz et al.	5,882,557			Hayakawa
5,529,070 A		Augustine et al.	5,891,034			Bucholz
5,540,235 A		Wilson	5,899,861 5,904,659		5/1999	Friemel et al.
5,558,092 A		Unger et al.	5,919,219			Knowlton
5,560,362 A 5,575,291 A		Sliwa et al. Hayakawa	5,923,099		7/1999	
5,575,807 A	11/1996		5,924,989		7/1999	Polz
5,577,502 A		Darrow et al.	5,928,169			Schatzle et al.
5,577,507 A	11/1996	Snyder et al.	5,931,805			Brisken
5,577,991 A		Akui et al.	5,938,606 5,938,612			Bonnefous Kline-Schoder
5,580,575 A		Unger et al.	5,948,011			Knowlton
5,601,526 A 5,603,323 A		Chapelon et al. Pflugrath et al.	5,957,844		9/1999	
5,609,562 A	3/1997		5,957,882			Nita et al.
5,615,091 A	3/1997	Palatnik	5,957,941		9/1999	
5,617,858 A		Taverna et al.	5,967,980 5,968,034		10/1999	Ferre et al.
5,618,275 A	4/1997		5,971,949		10/1999	
5,620,479 A 5,622,175 A		Diederich Sudol et al.	5,977,538			Unger et al.
5,638,819 A		Manwaring et al.	5,984,882			Rosenschein et al.
5,643,179 A		Fujimoto	5,990,598			Sudol et al.
5,644,085 A		Lorraine et al.	5,997,471			Gumb et al. Nita et al.
5,647,373 A		Paltieli	5,997,497 5,999,843		12/1999	
5,655,535 A 5,655,538 A		Friemel et al. Lorraine	6,004,262			Putz et al.
5,657,760 A	* 8/1997	Ying et al 600/439	6,007,499	A	12/1999	Martin et al.
5,658,328 A		Johnson	6,013,032		1/2000	
5,660,836 A		Knowlton	6,016,255			Bolan et al.
5,662,116 A		Kondo et al.	6,019,724 6,022,308			Gronningsaeter et al. Williams
5,665,053 A		Jacobs	6,022,308		2/2000	
5,665,141 A 5,671,746 A	9/1997 9/1997	Dreschel et al.	6,036,646		3/2000	
5,673,699 A		Trahey et al.	6,039,048		3/2000	Silberg
5,676,692 A		Sanghvi et al.	6,039,689		3/2000	
5,685,820 A	11/1997	Riek et al.	6,042,556			Beach et al.
5,687,737 A		Branham et al.	6,049,159 6,050,943		4/2000	Slayton et al 600/439
5,690,608 A		Watanabe	6,059,727			Fowlkes
5,694,936 A 5,697,897 A		Fujimoto et al. Buchholtz et al.	6,071,239			Cribbs et al.
5,701,900 A		Shehada et al.	6,080,108			Dunham
5,704,361 A		Seward et al.	6,083,148	A	7/2000	Williams
5,706,252 A		Le Verrier et al.	6,086,535			Ishibashi et al.
5,706,564 A	1/1998		6,086,580			Mordon et al.
5,715,823 A		Wood et al.	6,090,054			Tagishi
5,720,287 A		Chapelon et al. Suzuki et al.	6,093,883			Sanghvi
5,722,411 A	5/1998	SUZUKI EL AL.	6,101,407	A	o/2000	Groezinger

(56)	Re	feren	nces Cited	6,461,378 6,470,216			Knowlton Knowlton
	U.S. PAT	ENT	DOCUMENTS	6,488,626 6,491,657	B1		Lizzi et al.
6,106,469	A 8/3	2000	Suzuki et al.	6,500,121	B1*	12/2002	Slayton et al 600/439
6,113,558	A 9/2		Rosenschein et al.	6,500,141		12/2002	
6,113,559			Klopotek	6,508,774 6,511,427			Acker et al. Sliwa, Jr. et al.
6,120,452			Barthe	6,511,427			Azuma
6,123,081 6,126,619			Durette Peterson et al.	6,514,244		2/2003	
6,135,971			Hutchinson et al.	6,517,484		2/2003	Wilk et al.
6,139,499			Wilk	6,524,250		2/2003	
6,159,150			Yale et al.	6,540,679			Slayton et al 600/439 Rhoads et al.
6,171,244			Finger et al.	6,540,685 6,540,700			Fujimoto et al.
6,176,840 6,183,426			Nishimura Akisada	6,554,771			Buil et al.
6,183,502			Takeuchi	6,569,099			Babaev
6,183,773	B1 2/2		Anderson	6,569,108			Sarvazyan et al.
6,190,323			Digs	6,572,552 6,575,956			Fukukita Brisken et al.
6,190,336			Duarte	6,595,934			Hissong
6,193,658 6,210,327			Wendelken et al. Brackett et al.	6,599,256		7/2003	
6,213,948			Barthe	6,607,498	B2	8/2003	
6,216,029	B1 4/2	2001	Paltieli	6,618,620			Freundlich et al.
6,233,476			Strommer et al.	6,623,430 6,626,854			Slayton et al 600/439 Friedman
6,234,990			Rowe et al.	6,626,855		9/2003	Weng et al.
6,241,753 6,246,898			Knowlton Vesely et al.	6,638,226			He et al.
6,251,074			Averkiou et al.	6,645,162			Friedman
6,251,088			Kaufman et al.	6,662,054			Kreindel
6,268,405		2001		6,663,627			Francischelli
6,273,864			Duarte	6,665,806 6,666,835		12/2003	Shimizu Martin
6,280,402 6,287,257			Ishibashi et al. Matichuk	6,669,638			Miller et al.
6,296,619			Brisken	6,685,640		2/2004	
6,301,989			Brown et al.	6,692,450			Coleman
6,309,355			Cain et al.	6,699,237		3/2004	
6,311,090			Knowlton	6,716,184 6,719,449			Vaezy et al. Laugharn
6,315,741			Martin Pan et al.	6,719,694			Weng et al.
6,322,509 6,322,532			D'Sa	6,726,627		4/2004	Lizzi et al.
6,325,540			Lounsberry et al.	6,733,449			Krishnamurthy et al.
6,325,758	B1 12/2	2001	Carol et al.	6,749,624			Knowlton
6,325,769			Klopotek	6,773,409 6,775,404			Truckai et al. Pagoulatos et al.
6,325,798 6,338,716			Edwards et al. Hossack et al.	6,790,187			Thompson et al.
6,350,276			Knowlton	6,824,516		11/2004	Batten et al.
6,356,780			Licato et al.	6,835,940			Morikawa et al.
6,361,531			Hissong	6,846,290			Lizzi et al. Mourad
6,370,411			Osadchy et al.	6,875,176 6,882,884			Mosk et al.
6,375,672 6,377,854			Aksan Knowlton	6,887,239			Elstrom et al.
6,377,855	B1 4/2	2002	Knowlton	6,889,089	B2	5/2005	Behl
6,381,497	B1 4/2		Knowlton	6,896,657		5/2005	
6,381,498			Knowlton	6,902,536 6,905,466		6/2005	Manna et al.
6,387,380			Knowlton	6,918,907		7/2005	Kelly
6,390,982 6,405,090			Bova et al. Knowlton	6,920,883	B2	7/2005	Bessette
6,409,720			Hissong	6,921,371		7/2005	
6,413,216	B1 7/2	2002	Cain et al.	6,932,771			Whitmore
6,413,253			Koop	6,932,814 6,936,044		8/2005	Wood McDaniel
6,413,254	Bl 7/2	2002	Hissong Vitek	6,936,044			Hissong
6,419,648 6,423,007			Lizzi et al.	6,945,937			Culp et al.
6,425,865			Salcudean	6,948,843	B2	9/2005	Laugharn et al.
6,425,867			Vaezy et al.	6,953,941			Nakano et al.
6,425,912			Knowlton	6,958,043		10/2005	
6,428,477			Mason	6,971,994 6,974,417		12/2005	Young et al. Lockwood et al.
6,428,532 6,430,446	B1 8/2		Doukas Knowlton	6,976,492		12/2005	
6,432,057			Mazess et al.	6,992,305			Maezawa et al.
6,432,067	B1 8/2	2002	Martin	6,997,923	B2	2/2006	Anderson
6,432,101			Weber	7,006,874			Knowlton
6,436,061			Costantino	7,020,528		3/2006	
6,438,424			Knowlton	7,022,089		4/2006	
6,440,071 6,440,121			Slayton Weber	7,058,440 7,063,666			Heuscher et al. Weng et al.
6,443,914			Costantino	7,003,000			Vaezy et al.
6,453,202			Knowlton	7,074,218			Washington et al.
-,.55,252				,,= 20			<u> </u>

(56)	Referen	nces Cited	8,708,935 8,715,186			Barthe et al. Slayton et al.
U.S	PATENT	DOCUMENTS	8,726,781	B2	5/2014	Eckhoff et al.
			2001/0009997		7/2001	
7,094,252 B2	8/2006	Koop Talish et al.	2001/0009999 2001/0014780			Kaufman et al. Martin et al.
7,108,663 B2 7,115,123 B2		Knowlton	2001/0014819			Ingle et al.
7,122,029 B2	10/2006	Koop et al.	2001/0031922			Weng et al.
7,142,905 B2 *		Slayton et al 600/427	2001/0039380 2001/0041880		11/2001	Larson et al.
7,165,451 B1 7,179,238 B2		Brooks et al. Hissong	2002/0000763		1/2001	
7,189,230 B2	3/2007	Knowlton	2002/0002345			Marlinghaus
7,229,411 B2 *		Slayton et al 600/439	2002/0040199 2002/0040442		4/2002	Klopotek Ishidera
7,235,592 B2 7,258,674 B2		Muratoglu Cribbs	2002/0052550			Madsen et al.
7,273,459 B2		Desilets	2002/0055702		5/2002	
7,294,125 B2		Phalen et al.	2002/0062077 2002/0062142			Emmenegger et al. Knowlton
7,297,117 B2 7,303,555 B2		Trucco et al. Makin et al.	2002/0002142			Thompson et al.
7,303,333 B2 7,327,071 B2		Nishiyama et al.	2002/0082528	A1	6/2002	Friedman et al.
7,331,951 B2	2/2008	Eshel et al.	2002/0082529 2002/0082589			Suorsa et al.
7,332,985 B2	2/2008 3/2008	Larson, III et al.	2002/0082389			Friedman et al. Slayton et al.
7,347,855 B2 RE40,403 E		Cho et al.	2002/0095143		7/2002	
7,393,325 B2	7/2008	Barthe	2002/0099094			Anderson
7,398,116 B2		Edwards	2002/0115917 2002/0128648		9/2002	Honda et al. Weber
7,399,279 B2 7,491,171 B2		Abend et al. Barthe et al.	2002/0143252			Dunne et al.
7,510,536 B2		Foley et al.	2002/0156400		10/2002	
7,530,356 B2		Slayton	2002/0161357 2002/0165529		10/2002	Anderson
7,530,958 B2 7,571,336 B2		Slayton Barthe	2002/0168049			Schriever
7,601,120 B2		Moilanen et al.	2002/0169394			Eppstein et al.
7,615,015 B2		Coleman	2002/0169442 2002/0173721		11/2002	Neev Grunwald et al.
7,615,016 B2 7,686,763 B2	11/2009 3/2010	Barthe Vaezy et al.	2002/01/3721			Mchale et al.
7,695,437 B2		Quistgaard et al.	2002/0193831	A1	12/2002	Smith
7,758,524 B2	7/2010	Barthe	2003/0009153			Brisken et al.
7,789,841 B2		Huckle et al.	2003/0014039 2003/0018255		1/2003	Barzell et al. Martin
7,824,348 B2 7,846,096 B2		Barthe et al. Mast et al.	2003/0028111			Vaezy et al.
7,857,773 B2		Desilets et al.	2003/0028113			Gilbert et al.
7,875,023 B2 7,914,453 B2		Eshel et al. Slayton et al.	2003/0032900 2003/0036706		2/2003 2/2003	
7,914,455 B2 7,914,469 B2		Torbati	2003/0040739		2/2003	
7,931,611 B2		Novak et al.	2003/0050678		3/2003	Sierra
7,955,281 B2		Pedersen et al.	2003/0055417 2003/0060736		3/2003 3/2003	Truckai et al. Martin et al.
7,967,764 B2 7,967,839 B2		Lidgren et al. Flock et al.	2003/0065313		4/2003	Koop
8,057,389 B2*	11/2011	Barthe et al 600/437	2003/0074023		4/2003	
8,057,465 B2		Sliwa, Jr. et al.	2003/0083536 2003/0092988		5/2003 5/2003	
8,066,641 B2 8,123,707 B2		Barthe et al. Huckle et al.	2003/0097071			Halmann et al.
8,128,618 B2	3/2012	Gliklich et al.	2003/0099383			Lefebvre
8,133,180 B2 8,133,191 B2		Slayton et al.	2003/0125629 2003/0139790			Ustuner Ingle et al.
8,166,332 B2		Rosenberg et al. Barthe et al.	2003/0171678		9/2003	Batten et al.
8,197,409 B2	6/2012	Foley et al.	2003/0171701			Babaev
8,206,299 B2		Foley et al.	2003/0176790 2003/0191396			Slayton Sanghvi
8,211,017 B2 8,262,591 B2		Foley et al. Pedersen et al.	2003/0200481		10/2003	•
8,273,037 B2	9/2012	Kreindel et al.	2003/0212129			Liu et al.
8,282,554 B2		Makin et al.	2003/0212351 2003/0212393			Hissong Knowlton
8,333,700 B1 8,366,622 B2	2/2012	Barthe et al. Slayton et al.	2003/0212393		11/2003	
8,409,097 B2		Slayton et al.	2003/0220536			Hissong
8,444,562 B2		Barthe et al.	2003/0220585 2003/0229331		11/2003	Hissong Brisken et al.
8,480,585 B2 * 8,506,486 B2	7/2013 8/2013		2003/0233085	A1		Giammarusti
8,523,775 B2		Barthe et al.	2003/0236487			Knowlton
8,535,228 B2	9/2013		2004/0000316			Knowlton
8,585,618 B2 8,636,665 B2	11/2013 1/2014	Hunziker et al. Slayton et al.	2004/0001809 2004/0002705			Brisken Knowlton
8,641,622 B2		Barthe et al.	2004/0010222			Nunomura et al.
8,663,112 B2	3/2014	Slayton et al.	2004/0015106	A1	1/2004	Coleman
8,672,848 B2	3/2014		2004/0030227		2/2004	
8,690,778 B2 8,690,779 B2	4/2014 4/2014	Slayton et al. Slayton et al.	2004/0039312 2004/0039418			Hillstead Elstrom et al.
8,690,780 B2		Slayton et al.	2004/0033418			Lewin et al.
		-				

(56)		Referen	ces Cited	2006/0084891		4/2006 4/2006	
	II C	DATENT	DOCUMENTS	2006/0089632 2006/0089688			Panescu
	U.S.	FAIENI	DOCUMENTS	2006/0094988			Tosaya et al.
2004/0041880	A 1	3/2004	Ikeda et al.	2006/0111744		5/2006	
2004/0042168			Yang et al.	2006/0116583			Ogasawara et al.
2004/0044375	A1		Diederich et al.	2006/0116671			Slayton
2004/0049134	A1		Tosaya et al.	2006/0122508		6/2006	,
2004/0049734		3/2004		2006/0122509			Desilets Arditi et al.
2004/0059266		3/2004		2006/0161062 2006/0184069			Vaitekunas
2004/0068186 2004/0073079			Ishida et al. Altshuler et al.	2006/0184071			Klopotek
2004/0073079		4/2004		2006/0189972		8/2006	Grossman
2004/0073115			Horzewski et al.	2006/0206105		9/2006	
2004/0073116		4/2004		2006/0229514		10/2006	
2004/0073204			Ryan et al.	2006/0241440		10/2006	
2004/0077977			Ella et al.	2006/0241442 2006/0241470		10/2006	Novak et al.
2004/0082857		4/2004 4/2004	Schonenberger et al.	2006/0250046			Koizumi et al.
2004/0082859 2004/0102697		5/2004		2006/0261584			Blackburn
2004/0105559			Aylward et al.	2006/0282691	$\mathbf{A}1$	12/2006	
2004/0122323			Vortman et al.	2006/0291710			Wang et al.
2004/0122493	$\mathbf{A}1$	6/2004	Ishibashi et al.	2007/0032784			Gliklich et al.
2004/0143297			Ramsey	2007/0035201 2007/0055154		3/2007	Desilets Torbati
2004/0152982			Hwang et al.	2007/0055155			Owen et al.
2004/0158150 2004/0186535			Rabiner et al. Knowlton	2007/0055156			Desilets et al.
2004/0189155			Funakubo	2007/0065420			Johnson
2004/0206365			Knowlton	2007/0083120	$\mathbf{A}1$	4/2007	Cain et al.
2004/0210214			Knowlton	2007/0087060			Dietrich
2004/0217675	A1	11/2004		2007/0088245			Babaev et al.
2004/0249318		12/2004		2007/0088346 2007/0161902		4/2007 7/2007	Mirizzi et al.
2004/0254620			Lacoste et al.	2007/0161902		7/2007	
2004/0267252 2005/0033201			Washington et al. Takahashi	2007/0167709			Slayton
2005/0033201		2/2005		2007/0208253		9/2007	
2005/0038340			Vaezy et al.	2007/0219604	A1		Yaroslavsky et al.
2005/0055073		3/2005		2007/0219605			Yaroslavsky et al.
2005/0061834	A1		Garcia et al.	2007/0238994		10/2007	
2005/0070961			Maki et al.	2007/0239075 2007/0239079			Rosenberg et al. Manstein et al.
2005/0074407		4/2005		2007/0239079			Altshuler et al.
2005/0080469 2005/0091770		4/2005 5/2005	Mourad et al.	2008/0027328			Klopotek et al.
2005/0096542			Weng et al.	2008/0039724	A1	2/2008	Seip et al.
2005/0104690			Larson, III et al.	2008/0071255		3/2008	
2005/0113689			Gritzky	2008/0086054			Slayton
2005/0134314			Prather et al.	2008/0097253 2008/0139974			Pederson Da Silva
2005/0137656		6/2005		2008/0139974			Litman et al.
2005/0143677 2005/0154313			Young et al. Desilets	2008/0167556			Thompson et al.
2005/0154314			Quistgaard	2008/0183077	A1	7/2008	Moreau-Gobard et al.
2005/0154332		7/2005	Zanelli	2008/0188745			Chen et al.
2005/0154431	A1	7/2005	Quistgaard	2008/0195000			Spooner et al.
2005/0187495			Quistgaard	2008/0200810 2008/0200813			Buchalter Quistgaard
2005/0191252		9/2005		2008/0200813			Slayton
2005/0193451 2005/0197681			Quistgaard et al. Barolet et al.	2008/0221491			Slayton
2005/0228281		10/2005		2008/0223379		9/2008	Stuker et al.
2005/0240170			Zhang et al.	2008/0243035			Crunkilton
2005/0251120			Anderson et al.	2008/0269608			Anderson et al.
2005/0256406		11/2005		2008/0275342 2008/0281206		11/2008	Bartne Bartlett et al.
2005/0261584		11/2005		2008/0281200			Eshel et al.
2005/0261585 2005/0267454		12/2005	Makin et al.	2008/0281237		11/2008	
2005/0287434		12/2005		2008/0281255		11/2008	
2006/0004306			Altshuler	2008/0294073			Barthe et al.
2006/0020260	A1	1/2006	Dover et al.	2008/0319356			Cain et al.
2006/0025756			Francischelli	2009/0005680			Jones et al.
2006/0042201		3/2006		2009/0012394 2009/0043198			Hobelsberger et al. Milner et al.
2006/0058664 2006/0058671		3/2006	Barthe Vitek et al.	2009/0043198			Pankratov et al.
2006/0058671		3/2006		2009/0043293			Chen et al.
2006/0058707			Altshuler et al.	2009/0093737			Chomas et al.
2006/0074309			Bonnefous	2009/0156969		6/2009	
2006/0074313		4/2006	Slayton et al.	2009/0171252	A1	7/2009	Bockenstedt et al.
2006/0074314		4/2006	Slayton	2009/0177122			Peterson
2006/0074355		4/2006		2009/0177123			Peterson
2006/0079816		4/2006		2009/0182231			Barthe et al.
2006/0079868	Al	4/2006	wakin	2009/0216159	Al	8/2009	Slayton et al.

(56)	Referen	nces Cited		FOREIGN PA	ATEN	IT DOCUM	ŒNTS
U.S. 1	PATENT	DOCUMENTS	DE	10219217		11/2003	
			DE	10219297		11/2003	
2009/0226424 A1	9/2009		DE EP	20314479 0344773		3/2004 12/1989	
2009/0227910 A1 2009/0253988 A1	10/2009	Pedersen et al. Slayton et al.	EP EP	1479412		11/1989	
2009/0299175 A1		Bernstein et al.	EP	0473553	A	3/1992	
2009/0318909 A1		Debenedictis et al.	EP	0661029	A	7/1995	
2010/0011236 A1		Barthe et al. Peterson	EP EP	1050322 1234566		11/2000 8/2002	
2010/0022919 A1 2010/0022922 A1		Barthe et al.	EP	1262160		12/2002	
2010/0042020 A1		Ben-Ezra	EP	1374944	A	1/2004	
2010/0049178 A1		Deem et al.	GB JP	2113099		8/1983	
2010/0063422 A1 2010/0130891 A1		Hynynen et al. Taggart et al.	JP JP	63036171 03048299		2/1988 3/1991	
2010/0160782 A1	6/2010	Slayton et al.	JР	3123559		5/1991	
2010/0160837 A1		Hunziker et al.	JP	03136642		6/1991	
2010/0168576 A1		Poland et al.	JP JP	4089058		3/1992	
2010/0191120 A1 2010/0241035 A1		Kraus et al. Barthe et al.	JP JP	04150847 7080087		5/1992 3/1995	
2010/0280420 A1		Barthe et al.	JP	07505793		6/1995	
2010/0286518 A1		Lee et al.	JP	7222782		8/1995	
2011/0040171 A1		Foley et al.	JP JP	09047458 11505440		2/1997 5/1999	
2011/0040190 A1 2011/0087099 A1		Jahnke et al. Eshel et al.	JР	11505440		6/1999	
2011/0087255 A1		Mccormack et al.	JР	2000166940		6/2000	
2011/0112405 A1		Barthe et al.	JP	2001170068		6/2001	
2011/0178444 A1		Slayton et al.	JP JP	2002078764 2002515786		3/2002 5/2002	
2011/0190745 A1 2011/0264012 A1		Uebelhoer et al. Lautzenhiser et al.	JP	2002511118		7/2002	
2012/0004549 A1		Barthe et al.	JP	2002537939		11/2002	
2012/0016239 A1		Barthe et al.	JP	2003050298		2/2003	
2012/0029353 A1 2012/0035475 A1		Slayton et al. Barthe et al.	JP JP	2003204982 2004147719		7/2003 5/2004	
2012/0035475 A1 2012/0035476 A1		Barthe et al.	JP	2005503388		2/2005	
2012/0046547 A1		Barthe et al.	JP	2005527336		9/2005	
2012/0053458 A1		Barthe et al.	JP	2005323213		11/2005	
2012/0111339 A1		Barthe et al.	JP JP	2006520247 2007505793	Δ	9/2006 3/2007	
2012/0143056 A1 2012/0165668 A1		Slayton et al. Slayton et al.	JP	2009518126	11	5/2009	
2012/0165848 A1		Slayton et al.	JP	2010517695		5/2010	
2012/0197120 A1	8/2012	Makin et al.	KR KR	1020010024871 100400870	D1	3/2001 10/2003	
2012/0197121 A1		Slayton et al.	KR KR	1020060113930	DI	11/2006	
2012/0215105 A1		Slayton et al. Barthe et al.	KR	1020070065332		6/2007	
2012/0271294 A1 2012/0296240 A1		Azhari et al.	KR	1020070070161		7/2007	
2012/0316426 A1		Foley et al.	KR KR	1020070098856 1020070104878		10/2007 10/2007	
2012/0330197 A1		Makin et al.	KR	1020070104878		11/2007	
2012/0330222 A1		Barthe et al.	WO	9625888		8/1996	
2012/0330223 A1 2013/0012755 A1	1/2012	Makin et al.	WO	9639079	A1	12/1996	
2013/0012/33 A1 2013/0012816 A1		Slayton Slayton et al.	WO WO	9735518 9832379		10/1997 7/1998	
2013/0012838 A1		Jaeger et al.	wo	9933520		7/1999	
2013/0012842 A1		Barthe	WO	9949788		10/1999	
2013/0018286 A1		Slayton et al.	WO WO	0006032		2/2000	
2013/0046209 A1 2013/0066208 A1	2/2013	Slayton et al. Barthe et al.	WO	0015300 0021612		3/2000 4/2000	
2013/0066237 A1		Smotrich et al.	WO	0053113		9/2000	
2013/0072826 A1		Slayton et al.	WO	0128623		4/2001	
2013/0096471 A1	4/2013		WO WO	0182777 0182778		11/2001 11/2001	
2013/0190659 A1	7/2013	•	WO	0187161		11/2001	
2013/0211258 A1		Barthe et al. Slayton et al.	WO	0209813		2/2002	
2013/0281853 A1 2013/0281891 A1	10/2013 10/2013		WO	0224050		3/2002	
2013/0296697 A1		Slayton et al.	WO WO	02092168 02092168	Δ	11/2002 11/2002	
2013/0296700 A1	11/2013	Slayton et al.	WO	03053266		7/2003	
2013/0303904 A1		Barthe et al.	WO	03065347		8/2003	
2013/0303905 A1		Barthe et al.	WO WO	03070105		8/2003	
2013/0310863 A1 2014/0082907 A1		Barthe et al. Barthe	WO WO	03077833 03086215		8/2003 10/2003	
2014/0082907 A1 2014/0142430 A1	5/2014		WO	03096883		11/2003	
2014/0148834 A1		Barthe et al.	WO	03099177		12/2003	
2014/0180174 A1	6/2014		WO	03101530		12/2003	
2014/0187944 A1		Slayton et al.	WO WO	2004000116	A	12/2003	
2014/0188015 A1 2014/0188145 A1	7/2014 7/2014	Slayton et al. Slayton et al.	WO WO	2004080147 2004110558		9/2004 12/2004	
2017/010017J A1	112017	Sayton et al.	., 0	2007110550		12/2007	

(56)References Cited FOREIGN PATENT DOCUMENTS WO 2005011804 A 2/2005 WO 2005065408 7/2005 WO 2005090978 9/2005 WO 2006036870 4/2006 WO 2006042163 A 4/2006 WO 2006042168 4/2006 WO 2006042201 4/2006 WO 2006065671 6/2006 WO 2006082573 8/2006 WO 2007067563 A 6/2007 WO 2008024923 A2 2/2008 WO 2008036622 A 3/2008 WO 2009013729 1/2009 WO 2009149390 A1 12/2009 WO 2014055708 A1 4/2014

European Examination Report in related Application No. 05810308.6 dated Jun. 29, 2009.

OTHER PUBLICATIONS

European Examination Report in related Application No. 10185100.4 dated Jan. 6, 2014.

European Examination Report in related Application No. 10185120.2 dated Jan. 22, 2014.

Decision of the Korean Intellectual Property Tribunal dated Jun. 28, 2013 regarding Korean Patent No. 10-1142108, which is related to the pending application and/or an application identified in the Table on the pp. 2-5 of the information Disclosure Statement herein (English translation, English translation certification, and Korean decision included).

International Search Report and Written Opinion dated Jan. 23, 2014 in Application No. PCT/US2012/046122.

International Search Report and Written Opinion dated Jan. 23, 2014 in Application No. PCT/US2012/046123.

International Search Report and Written Opinion dated Jan. 28, 2012 in Application No. PCT/US2012/046327.

International Search Report and Written Opinion dated Jan. 28, 2013 in Application No. PCT/US2012/046125.

International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001361.

International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001362.

International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001366.

Alster, Tinas S., Tanzi, Elizabeth L., "Cellulite Treatment using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device," Journal of Cosmetic & Laser Therapy, Jun. 2005, vol. 7, Issue 2, pp. 81-85.

Arthur et al., "Non-invasive estimation of hyperthermia temperatures with ultrasound," Int. J. Hyperthermia, Sep. 2005, 21(6), pp. 589-600

Barthe et al., "Ultrasound therapy system and abiation results utilizing miniature imaging/therapy arrays," Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1792-1795, vol. 3.

Chen, L. et al., ""Effect of Blood Perfusion on the ablation of liver perenchyma with high intensity focused ultrasound," Phys. Med. Biol; 38:1661-1673; 1993b.

Coon, Joshua et al., "Protein identification using sequential ion/ion reactions and tandem mass spectometry" Proceedings of the National Academy of Sciences of the USA, vol. 102, No. 27, Jul. 5, 2005, pp.

Corry, Peter M., et al., "Human Cancer Treatment with Ultrasound", IEEE Transactions on Sonics and Ultrasonics, vol. SU-31, No. 5, Sep. 1984, pp. 444,456.

Damianou et al., Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery, "1993 IEEE Ultrasound Symposium, pp. 1199-1202.

Daum et al., "Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery," IEEE Transactions on Ultrasonics, Feroelectronics, and Frequency Control, vol. 45, No. 2, Mar. 1998, pp. 431-438.

Davis, Brian J., et al., "An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues", 1985 Ultrasonics Symposium, pp. 921-924.

Fry, W.J. et al., "Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound," J. Neurosurg., 11:471-478: 1954.

Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, Arch Facial Plastic Surgery, Mar. 1, 2007, vol. 9.

Harr, G.R. et al., "Tissue Destruction with Focused Ultrasound in Vivo," Eur. Urol. 23 (suppl. 1):8-11; 1993.

Hassan et al., "Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods," advanced in Polymer Science, 2000, pp. 37-65, vol. 153.

Hassan et al., "Structure and Morphology of Freeze/Thawed PVA Hydrogels," Macromolecules, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7.

Husseini et al, "The Role of Cavitation in Acoustically Activated Drug Delivery," J. Control Release, Oct. 3, 2005, pp. 253-261, vol. 107(2).

Husseini et al. "Investigating the mechanism of accoustically activated uptake of drugs from Pluronic micelles," BMD Cancer 2002, 2:20k, Aug. 30, 2002, pp. 1-6.

International Search Report and Written Opinion dated Apr. 6, 2012 in Application No. PCT/US2011/001367.

Jeffers et al., "Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms," 1993 IEEE Ultrasonics Symposium, pp. 925-928.

Jenne, J., et al., "Temperature Mapping for High Energy US-Therapy", 1994 Ultrasonics Symposium, pp. 1879-1882.

Madersbacher, S. et al., "Tissue Ablation in Bening Prostatic Hyperplasia with High Intensity Focused Ultrasound," Dur. Urol., 23 (suppl. 1):39-43; 1993.

Makin et al, "B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays," Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3.

Makin et al, "Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging," UltraSound Med. Biol. 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11).

Makin et al., "Confirmal Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays", 4th International Symposium on Therapeutic Ultrasound, Sep. 19, 2004.

Manohar et al, "Photoaccoustic mammography laboratory prototype: imaging of breast tissue phantoms," Journal of Biomedical Optics, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6.

Mast et al, "Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling nad Experiments," J. Acoust. Soc. Am., Oct. 1, 2005, pp. 2715-2724, vol. 118(4).

Paradossi et al., "Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications," Journal of Materials Science: Materials in Medicine, 2003, pp. 687-691, vol. 14.

PCT/US2012/046122 International Search Report Jan. 30, 2013.

PCT/US2012/046123 International Search Report Jan. 28, 2013.

PCT/US2012/046125 International Search Report Jan. 28, 2013.

Reid, Gavin, et al., "Tandem Mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions," Analytical Chemistry. Feb. 1, 2002, vol. 74, No. 3, pp. 577-583.

Righetti et al, "Elastographic Characterization of HIFU-Induced Lesions in Canine Livers," 1999, Ultrasound in Med & Bio, vol. 25, No. 7, pp. 1099-1113.

Saad et al., "Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors," Ultrasound in Med. & Biol. vol. 18, No. 8, pp. 715-723 (1992).

Sanghvi, N.T., et al., "Transrectal Ablation of Prostrate Tissue Using Focused Ultrasound," 1993 Ultrasonics Symposium, IEEE, pp. 1207-1210.

Sassen, Sander, "ATI's R520 architecture, the new king of the hill?" http://www.hardwareanalysis.com/content/article/1813, Sep. 16, 2005, 2 pages.

Seip, Ralf, et al., "Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fiels," IEEE Symposium, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993.

(56) References Cited

OTHER PUBLICATIONS

Seip, Ralf, et al., "Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound," IEEE Transactions on Biomedical Engineering, vol. 42, No. 8, Aug. 1995, pp. 828-839.

Simon et al., "Applications of Lipid-Coated Microbubble Ultrasonic Contrast to Tumor Therapy," Ultrasound in Med & Biol. vol. 19, No. 2, pp. 123-125 (1993).

Smith, Nadine Barrie, et al., "Non-Invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques", 1994 Ultrasonics Symposium, pp. 1829-1832, vol. 3.

Surry et al., "Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging," Phys. Med. Biol., Dec. 6, 2004, pp. 5529-5546, vol. 49.

Syka J. E. P. et al., "Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectometry," Proceedings of the National Academy of Sciences of USA, National Academy of Aceince, Washington, DC, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533.

Talbert, D. G., "An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays," UTS Int'l 1977 Brighton, England (Jun. 28-30, 1977) pp. 57-67.

Tata et al., "Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions," American Chemical Society, Phys. Chem. 1992, 96, pp. 3548-3555.

Ueno, S., et al., "Ultrasound Thermometry in Hyperthermia", 1990 Ultrasonic Symposium, pp. 1645-1652.

Wang, H., et al., "Limits on Focused Ultrasound for Deep Hyperthermia", 1994 Ultrasonic Symposium, Nov. 1-4, 1994, pp. 1869-1872, vol. 3.

Wasson, Scott, "NVIDIA's GeFroce 7800 GTX graphics processor Power MADD," http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1, Jun. 22, 2005, 4 pages.

White et al "Selective Creation of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy," Arch Facial Plastic Surgery, Jan./Feb. 2007, vol. 9, No. 1. Calderhead et al, One Mechanism Behind LED Photo-Therapy for Wound Healing and Skin Rejuvenation: Key Role of the Mast Cell, Laser Therapy, Jul. 2008, pp. 141-148, 17.3.

European Examination Report in related Application No. 09835856.7 dated Apr. 11, 2004.

International Search Report and Written Opinion dated Apr. 6, 2012 in Application No. PCT/US2011/001366.

PCT International Search Report and Written Opinion, PCT/US2014/030779, Sep. 1, 2014, 8 pages.

European Patent Office, Examination Report, EP 07814933.3, Aug. 5, 2014, 5 pages.

European Patent Office, Examination Report, EP 05798870.1, Oct. 20, 2014, 5 pages.

European Patent Office, Examination Report, EP 10185100.4, Oct. 24, 2014, 4 pages.

European Patent Office, Examination Report, EP 10185112.9, Oct. 24, 2014, 5 pages.

European Patent Office, Examination Report, EP 10185117.8, Oct. 24, 2014, 5 pages.

European Patent Office, Examination Report, EP 10185120.2, Oct. 24, 2014, 4 pages.

* cited by examiner




FIG.1




FIG.2




FIG.3




FIG.4




FIG.5






FIG.6


Mar. 1, 2016





BOUNDARY (NATURAL OR ARTIFICIAL)


FIG.7

















FIG.11




FIG.12




FIG.13




FIG.14

IMAGING, THERAPY, AND TEMPERATURE MONITORING ULTRASONIC METHOD

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 11/744,655, filed May 4, 2007 and which is U.S. Pat. No. 8,480,585, which application is a continuation of U.S. patent application Ser. No. 10/193,419, filed on Jul. 10, 10 2002 and which is now U.S. Pat. No. 7,229,411, which application is a continuation of U.S. patent application Ser. No. 08/950,353 filed on Oct. 14, 1997 and which is now U.S. Pat. No. 6,050,943, and is also a continuation-in-part of U.S. patent application Ser. No. 09/502,174, filed on Feb. 10, 2000 15 and which is now U.S. Pat. No. 6,500,121, all of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention generally relates to a non-invasive therapeutic ultrasonic system, and more particularly, to a system which is capable of acoustically imaging and heating a certain region to be treated ("the treatment region") in target tissue 25 for therapeutic purposes as well as acoustically monitoring the temperature profile of the treatment region.

2. Description of the Related Art

The absorption of energy in tissue, for example, in the human body produces an increase in temperature, which can be exploited for therapeutic purposes. The irradiation of ultrasound to the target tissue such as in the human body, which has been successfully used for decades mainly in increasingly sophisticated diagnostic imaging applications, also allows the target tissue to absorb a certain amount of energy. Thus, tional acoustic transducers. In general, for the therapeutic uses.

Specifically, ultrasonic energy at frequencies above 1.5 MHZ has an acoustic wavelength less than 1 mm in the human tissue. This energy is easily controlled in beamwidth and depth of penetration, and has a favorable absorption characteristic in the tissue. These aspects allow the energy to be precisely localized such that regions may be selectively heated while sparing overlying tissue structures.

Ultrasound has significant advantages for therapeutic applications as compared to micro-wave radio-frequency 45 (RF) energy or optical energy (laser light).

In contrast with the ultrasound, the RF energy is characterized by long wavelengths in the tissue, with limited to poor control of energy deposition, and high absorption.

These aspects of the RF energy constrain its therapeutic 50 usage to large superficial areas. On the other hand, the optical energy which is typically emitted from lasers can be precisely controlled in beamwidth, but the opacity and high absorption in the tissue also limits its use to surface treatment or invasive procedures. Furthermore, the laser and RF energy are emitted 55 from ionizing radiation sources which are typically associated with some risk, unlike acoustic transducers which are typically used for generating ultrasound.

However, in contrast with the diagnostic uses, the therapeutic uses of ultrasound such as hyperthermia and non-invasive surgery have seen relatively little progress due to several technological barriers.

The primary impediment has been a lack of the ability to monitor temperature in the treatment region during the therapeutic treatment process.

Specifically, one of objectives of the therapeutic application is to create a very well-placed thermal gradient in the 2

target tissue to selectively destroy certain regions thereof. For example, hyperthermia technique typically requires to maintain the tissue temperature near about 43 degrees Celsius, while the goal of non-invasive surgery is typically to elevate the tissue temperature above and beyond about 55 degrees Celsius. Moreover, during the therapeutic treatment process, the physiological response of the target tissue is directly related to the spatial extent and temporal duration of the heating pattern. Consequently, in order to appropriately perform feedback and control of the therapeutic treatment process for obtaining successful results, it is absolutely essential to monitor the temperature in the target tissue, for example, so as to know whether or not the temperature in the treatment region has been raised to a level that produces a desired therapeutic effect or destruction in the tissue. In addition, it is preferable to know the temperature distribution in the treatment region and the vicinity thereof for enhancing the therapeutic effect.

In the conventional technique, the therapeutic ultrasonic system has typically relied upon thermocouple probes for monitoring the temperature in the treatment region and the vicinity thereof. However, the thermocouple probes are highly invasive because they have to be inserted into the region-of-interest. In addition, use of the thermocouple probes has necessarily led to very poor spatial resolution since only a small number of probes could be safely embedded in the region-of-interest. Furthermore, the thus embedded thermocouple probes are likely to disturb the acoustic propagation in the tissue and typically cause excessive heating at the probe interface during the therapeutic treatment process. This results in undesirably modified temperature distribution as well as erroneous measurements.

Another factor which has curtailed progress in the therapeutic uses of ultrasound has been the design of the conventional acoustic transducers.

In general, for the therapeutic treatment process, imaging of the treatment region is necessary to determine the location of the treatment region with respect to the acoustic transducers as well as to evaluate progress of the treatment process.

Such essential functions of imaging as well as the aforementioned temperature monitoring may be implemented with the same acoustic transducer to be used for the therapeutic purposes, since the acoustic transducers can actually produce an image of the region-of-interest by employing wellestablished imaging technique such as B-scan imaging. However, the conventional acoustic transducers which are typically employed for the therapeutic purposes are acoustically large, often single-element devices having narrow bandwidth in the frequency domain. Although they are designed to efficiently transmit acoustic energy to the target tissue, the conventional acoustic transducers are typically unsuited for imaging of the treatment region and/or monitoring the temperature profile therein. This precludes development and implementation of these vital functions for performing a desirable precise therapeutic treatment process.

Some prior art references teach the use of ultrasound for therapeutic purposes. For example, U.S. Pat. No. 4,757,820 to Itoh discloses an ultrasound therapy system having functions of imaging and heating the target using ultrasound beams for the therapeutic purposes. The system disclosed therein, however, does not have the temperature monitoring function.

U.S. Pat. No. 5,370,121 to Reichenberger et al. discloses a method and an apparatus for non-invasive measurement of a temperature change in a subject, in particular a living subject, using ultrasound waveforms. The method and apparatus disclosed therein, however, relies on a differential ultrasound image between two successive ultrasound images of the tar-

get. In other words, any temperature change is detected as a temperature-induced change in brightness between the two images, which appears in the differential image. Consequently, an actual real-time monitoring of the temperature may be difficult in the disclosed method and apparatus. Moreover, although the method and apparatus can detect changes in the temperature of the target, an absolute value of the target temperature may not be obtained therefrom. In addition, any movement of the target may introduce changes in the differential image, which may cause erroneous results.

Furthermore, although it is not distinctly intended to be applied in the therapeutic treatment process for the target tissue such as in the human body, U.S. Pat. No. 5,360,268 to Hayashi et al. discloses an ultrasonic temperature measuring apparatus in which a temperature of the target, medium is calculated using a propagation time of ultrasonic waves which propagated for a predetermined distance in the target medium. The apparatus disclosed therein, however, is mainly described as employing separate ultrasonic elements which respectively function for a transmitter and a receiver of the 20 ultrasonic waves.

While some prior art temperature monitoring techniques exist, see, for example, U.S. Pat. No. 4,807,633 issued to Fry on Feb. 28, 1989, such techniques are complex and have limited applicability. That is, use of such techniques essentially preclude use of the system for purposes of imaging, unless one were to use multiple transducers. In that regard, while two or more physically separated transducers can be used to accomplish imaging and therapy, typically with one configured for imaging and the other for therapy, such a system is susceptible to the generation of imprecise data and is overly complex and expensive.

Thus, it would be advantageous to provide a compact, non-invasive system capable of acoustically performing the therapeutic heating and the imaging of the treatment region in the treatment region with a single acoustic transducer. Moreover, it would also be advantageous to provide a compact, non-invasive system capable of performing three-dimensional imaging, temperature monitoring and therapeutic heating of the treatment region to provide a more focused therapeutic treatment process.

In other applications, it would be advantageous to provide therapeutic ultrasonic systems with multiple transducers capable of facilitating the imaging, temperature monitoring, 45 and therapeutic heating functions to obtain imaging and temperature information over a larger area of the region-of-interest and provide therapeutic heating more appropriately to the target tissue, for example, over a larger region-of-interest, with an increased intensity at the treatment region, or more 50 readily focused towards the target tissue.

SUMMARY OF THE INVENTION

In accordance with various aspects of the present invention, a non-invasive therapeutic ultrasonic system is provided, which features a single acoustic transducer and some other subsystems capable of acoustically performing therapeutic heating and imaging of the treatment region as well as acoustically monitoring, the temperature profile in the treatment region and the vicinity thereof. Also disclosed herein is a system architecture and associated components as well as algorithms which can be implemented to acoustically achieve the heating, imaging, and temperature monitoring functions. The imaging and monitoring functions allow precise feedback and control of the therapeutic treatment process so that the therapy can be conducted more successfully. In addition,

4

because a single transducer is utilized perfect correspondence is obtained; that is, image artifacts and/or imprecise registration difficulties yielded through use of multiple transducers can be avoided

A novel acoustic transducer disclosed herein is capable of generating high acoustic power for the therapeutic treatment process, while at the same time providing a good imaging function. Specifically, in order to obtain good lateral resolution in the imaging process, the acoustic transducer of the present invention is preferably divided into an array of subelements, each processing acoustic waves with a sufficient bandwidth for good axial resolution in the imaging process.

These imaging requirements are also extended to the acoustic temperature monitoring function of the treatment region. In accordance with various aspects of the present invention, an acoustic temperature measurement subsystem disclosed herein is capable of non-invasively mapping the temperature distribution or profile in the target tissue in realtime. This feature is accomplished by measuring the time-offlight and amplitude data of acoustic pulses through the region-of-interest while exploiting the temperature dependence of the speed of sound and acoustic attenuation in the target tissue. The acoustic nature of this process allows the same acoustic transducer which is used for the imaging and therapy functions to be used for the real-time temperature monitoring function. Alternatively, the use of the multiple acoustic transducers allows the temperature mapping to be conducted with a higher spatial resolution. The thus gathered valuable information on the temperature in the target tissue can be used to achieve precise control of the spatial distribution of heating, detailed knowledge of the heating duration, and quantitative temperature data during the therapeutic treatment process, which has not been previously possible in the conventional art.

In accordance with other aspects of the present invention, the acoustic transducers disclosed herein can be configured to provide three-dimensional imaging, temperature mapping and therapeutic heating of the treatment region.

These three-dimensional features may be realized by any number of methods, such as, for example, the use of adaptive algorithms or the use of mechanical scanning devices.

Additional aspects of the present invention may include the ability to provide therapeutic ultrasonic systems with multiple transducers capable of facilitating the imaging, temperature monitoring, and therapeutic heating functions to obtain imaging and temperature information over a larger area of the region-of-interest and provide therapeutic heating more appropriately to the target tissue, for example, over a larger region-of-interest, with an increased intensity at the treatment region, or more readily focused towards the target tissue.

BRIEF DESCRIPTION OF THE DRAWINGS

Preferred exemplary embodiments of the present invention is described in conjunction with the appended drawing figures in which like numerals denote like elements, and:

FIG. 1 is a cross-sectional view of an acoustic transducer assembly according to the present invention;

FIG. 2 is a diagram of an imaging subsystem interfaced to the acoustic transducer assembly according to the present invention;

FIG. 3 is a diagram of a therapy subsystem interfaced to the acoustic transducer assembly according to the present invention;

FIG. 4 is a diagram illustrating a temperature monitoring subsystem according to the present invention;

FIG. 5 depicts waveforms of heated and unheated states illustrating the time shift and amplitude change of the echo in the region of interest;

FIG. **6** is a diagram of a further embodiment of a temperature monitoring subsystem interfaced to the acoustic trans- 5 ducer assembly according to the present invention;

FIG. 7 is a depiction of the intersecting paths of acoustic rays possible from a transducer source;

FIG. 8 illustrates a tomographic configuration useful in connection with yet another embodiment of a temperature 10 monitoring subsystem according to the present invention;

FIGS. 9A-D show the characteristics of an exemplary transducer made in accordance with various aspects of the present invention;

FIGS. 10A-B show, respectively, the pulse echo waveform 15 and the frequency spectrum of the echo of an exemplary transducer made in accordance with various aspects of the present invention;

FIG. 11 is a diagram of an exemplary embodiment of an ultrasonic system having three-dimensional imaging and ²⁰ temperature monitoring capabilities;

FIG. 12 is a diagram of another exemplary embodiment of an ultrasonic system having additional capabilities for providing imaging and temperature monitoring over a region-ofinterest.

FIG. 13 is a diagram of yet another exemplary embodiment of an ultrasonic system having multiple transducers; and

FIG. 14 is a diagram of an exemplary embodiment of a two dimensional imaging array.

DETAILED DESCRIPTION

A system for achieving successful ultrasonic therapy procedures in accordance with the present invention includes four major subsystems or components. Specifically, they are 35 an acoustic transducer assembly, an imaging subsystem, a therapy subsystem (also referred to as a "therapeutic heating subsystem"), and a temperature monitoring subsystem, which are illustrated in FIGS. 1 through 4, respectively. Although not shown in the drawing figures, the system further 40 includes components typically associated with a therapy system, such as any required power sources, memory requirements, system control electronics, and the like.

With reference to FIG. 1, the acoustic transducer assembly 100 included in the system of the present invention will be 45 described in detail below. As shown in the cross-sectional view of FIG. 1, the acoustic transducer assembly 100 includes a piezoelectric ceramic plate 10. The air-backed side of the ceramic plate 10 is partially diced to have a plurality of curved (e.g. concave) portions **15** to form a linear array structure. The 50 thickness of the diced ceramic plate is selected to provide a center frequency for example from 500 kHz to 20 MHZ, with lower frequencies yielding deeper penetration and higher frequencies providing greater resolution. The concave portions 15 constituting the transducer array are spaced to achieve 55 good lateral resolution in the imaging function. On the face of each of the concave portions 15, a metal electrode 20 is provided to connect the ceramic plate 10 to the system control electronics (not shown in the figure) via a cable 30 and a terminal 40. The other face of the ceramic plate 10 is config- 60 ured such as to receive a common metal electrode 25. The common electrode 25 is also connected to the system control electronics via a cable 35 and a terminal 45.

In addition, although a concave portion is described above, it should also be noted that portion **15** may also comprise a 65 substantially flat configuration with a natural locus arrangement, e.g., without a focusing lens. Moreover, portion **15** can

6

also be configured with a substantially flat configuration having a convex or concave lens arrangement. Accordingly, portion 15 may be configured in various manners without departing from the scope of the present invention.

The phrase "air-backed" means that there is no backing material provided on the back side of the acoustic transducer assembly 100, unlike the typical conventional acoustic transducers. Specifically, the conventional acoustic transducers are typically provided with some kinds of the backing layer typically made of a loaded epoxy, such as an alumina powder epoxy. The loaded particles in the backing layer, however, introduces increased acoustic impedance as well as providing scattering surfaces therein. Accordingly, when the generated acoustic waves come to the backing layer and hit the loaded particles included therein, the particles tend to disburse the acoustic waves in different directions into the epoxy matrix so that attenuation increases. As a result, the operational efficiency of the acoustic transducer decreases since some portion of the generated acoustic energy is absorbed in the backing layer. On the other hand, in the acoustic transducer assembly 100 of the present invention, by providing no backing layer on the back end of the ceramic plate 10, the acoustic waves are reflected without being absorbed there to propagate toward the target tissue, resulting in the increased efficiency.

Alternatively, a certain backing layer may be provided as long as it has a very low acoustic absorption so that any significant absorption of the generated acoustic energy does not happen.

On the common electrode 25, one or more acoustic matching layers 50 is bonded using an adhesive such as an epoxy.
When a loaded epoxy is used as the adhesive, the acoustic
matching layer 50 can be simply cast thereon since they
adhere naturally to each other. The acoustic matching layer 50
is intended to obtain appropriate impedance matching
between the ceramic plate 10 and the target tissue. Consequently, efficient transfer of acoustic power from the ceramic
plate 10 to the target tissue can be maintained to achieve an
appropriate temperature increase in the target tissue, resulting
in desired therapeutic results. When the acoustic matching
layer 50 (or layers) is bonded to the ceramic plate 10 (precisely, to the common electrode 25) with a loaded epoxy, the
acoustic impedance can be easily adjusted by changing the
amount of metal particles loaded in the epoxy.

At the same time, acoustic matching layer(s) **50** can increase the bandwidth of the emitted acoustic waves in the frequency domain. This aspect is suitable for the effective imaging function.

Specifically, in order to improve the sensitivity in the imaging function, it is preferable that the emitted acoustic waves are very pulsive in the time domain since acoustic pulses with a very short pulse width can produce clearly distinct echoes from different interfaces existing in the target tissue. The shorter the width of the acoustic pulses is, the more clearly the distinct echoes can be resolved, resulting in improved resolution in the obtained images. The short pulse in the time domain means a wide range in the frequency domain which covers a large spectrum. On the other hand, however, when considering an efficient transmission of the acoustic energy from the acoustic transducer assembly 100 to the target tissue which is important for the therapeutic treatment process, it is preferable to use stable acoustic waves such as "continuous waves" or gated bursts, which in turn means that the bandwidth thereof in the frequency domain is narrow. Thus, tradeoff between the efficiency in the therapeutic function and the sensitivity in the imaging function has to be satisfied by appropriately setting the bandwidth of the acoustic waves to be emitted.

Without acoustic matching layer(s) **50**, the bandwidth of the emitted acoustic waves is determined mainly based on the design of the ceramic plate **10** which actually generates the acoustic waves. This results in the limited degrees of freedom for adjusting the bandwidth. Providing one or more acoustic matching layer(s) **50** makes it possible to properly adjust the bandwidth in a wide range without substantially changing the design of the ceramic plate **10**.

Typically, the thickness of the acoustic matching layer 50 is set to be on the order of a quarter of a wavelength, of the acoustic waves. In addition, it is preferable that the acoustic impedance of the acoustic matching layer 50 be set to be approximately equal to the square root of the acoustic impedance of the ceramic plate 10 times the acoustic impedance of the target tissue or, more preferably, the acoustic impedance of the ceramic plate raised to the .THETA. power, times the acoustic impedance of the target tissue raised to the K power. Also, multiple matching layers may be used, of course, with suitable changes in layer impedances.

The acoustic matching layer 50 can be made of various types of materials, such as ceramics, plastics, metals and a composite material thereof. Preferably the matching layer may exhibit good thermal conductivity and low acoustic attenuation.

Matching layer (or layers) 50 may be cut or diced, such as shown on FIG. 1, to maintain high acoustic isolation, i.e., low acoustic crosstalk. However, any heating of the matching layer(s) of ceramic may be controlled via the duty cycle of the drive signal or via active or passive cooling methodologies. In 30 addition, any other conventional cooling technique and/or methodology may be utilized.

Although not shown on FIG. 1, it should be appreciated that transducer assembly 100 may be provided with a back layer (not shown) suitably configured to modify the bandwidth of the transducer and/or serve as a heat sink.

The ceramic plate 10 and other related components configured as set forth above are coupled to the target tissue via a fluid 70 circulating between the acoustic matching layer 50 and an acoustically-transparent membrane 60. The fluid 70 40 also functions as a coolant for the ceramic plate 10 and the acoustic matching layer 50 and may also aid in controlling the temperature of the tissue at the interface.

Temperature control via a circulating fluid, thermoelectric cooling module and/or pneumatic or other devices may also 45 be utilized in accordance with various aspects of the present invention. Furthermore, the acoustic transducer assembly 100 having the aforementioned configuration is enclosed in a water-tight housing (not shown in the figure).

The circulating fluid 70 has two major functions as mentioned above. One of them is to couple the ceramic plate 10 and the acoustic matching layer 50 to the target tissue. The other is to remove the waste heat away from the acoustic transducer assembly 100. In particular, the energy conversion efficiency of the acoustic transducer assembly 100 is typically about 80%, and consequently, some portion of the input electrical power becomes the waste heat. When a large amount of electrical power is input to the acoustic transducer assembly 100, the assembly 100 is heated up. This may result in reduced efficiency and altered operational characteristics, which are likely to produce adverse effects on the therapeutic purposes. The circulating fluid 70 therefore keeps the acoustic transducer assembly 100 at a stable and constant temperature by cooling it off.

The fluid **70** is typically water. Alternatively, any suitable 65 mineral oil, plant oil, or other suitable liquid could be used as the fluid **70**.

8

With reference to FIG. 2, an imaging subsystem 200 which is interfaced to the acoustic transducer assembly 100 is described below. The imaging subsystem 200 connected to the acoustic transducer assembly 100 via a cable 210 includes a beam forming control unit. The unit is operated so that the acoustic transducer assembly 100 scans the region-of-interest, including the treatment region, in the target tissue 800 with the acoustic waves. The returning acoustic signal is received by the acoustic transducer assembly 100, and then sent to the imaging subsystem 200 to generate ultrasonic images of the treatment region. The thus generated image is displayed on a video display terminal 500 to assist the user in appropriately positioning the acoustic transducer assembly 100 with respect to the treatment region in the target tissue 15 **800** prior to actually commencing the therapeutic treatment process.

With reference to FIG. 3, a therapy subsystem (a therapeutic heating system) 300 which is interfaced to the acoustic transducer assembly 100 is described below.

The therapy subsystem 300 connected to the acoustic transducer assembly 100 via a cable 310 includes power RF drivers which are interfaced to the linear array of the acoustic transducer assembly 100, i.e., to each of the respective portions 15 of the ceramic plate 10 shown in FIG. 1. The power 25 RF drivers are also connected to the common electrode 25 provided on the other face of the ceramic plate 10. By appropriately applying RF signal voltages to the ceramic plate 10 from the thus connected power RF drivers, high power acoustic energy is generated. The drivers are controlled in-time so that the acoustic transducer assembly 100 transmits, steers, and/or focuses the acoustic waves to the region-of-interest including the treatment region in the target tissue 800. Heating power and heating time as well as transducer anodization are all controlled during the therapeutic treatment process to achieve the proper heating pattern and therapeutic dosage. The control can be supplemented by the feedback of information from the temperature monitoring subsystem described later.

In connection with yet another embodiment of the present invention, temperatures are monitored in a manner calculated to avoid tissue motion artifacts. For example, in the case where a localized region is heated, in accordance with this embodiment of the present invention, the heated region is interrogated with a pulse echo signal substantially immediately thereafter. In such a case the echo from the heated region will be changed in time and amplitude. For example, the acoustic attenuation in tissue approximately doubles from 50° C. to 70° C. Preferably, the region is measured immediately before and after heating and thus, tissue motion artifacts are avoided, as well as any acoustic propagation effects.

In the case where only a small region is treated at a time, an isothermal region about the hot spot is engendered. Therefore, the time-of-flight and the amplitude of wave incident on the heated region is the same before and after the therapeutic energy is delivered. Thus, the amplitude change and time change measured after therapy will be due substantially to the tissue treated.

With reference to FIG. 4, a general schematic utilizing this approach is shown where transducer assembly 100 is used to heat a small region 800. As shown, the temperature monitoring subsystem 400 is connected to display 500.

Temperature monitoring subsystem 400 is also connected to transducer assembly 100, such as by a suitable cable 410. In accordance with this aspect of the present invention, the whole volume is scanned, and by sweeping the pulse echo the effective thermal dose (time/temperature history) (e.g. recrossed volume) can be determined. In the context of the

(

present invention the term thermal dose relates to the temperature and time of duration integral function by which, for example, a determination of necrosity can be made.

With reference to FIG. **5**, the echo waveform in a windowed region of a waveform A obtained before heating and a waveform B after heating can be examined, and based on the time-duration and spatial extent of the heated area, i.e. the time shift of the echo in the heated region and tissue and thermal properties, the temperature can be determined.

Alternatively, instead of evaluating the time shift, the echo amplitude in the windowed region could be examined. In accordance with this aspect of this embodiment of the present invention, when the amplitude of the signal in the windowed region begins to rapidly fall, the temperature will be in the 50° C. to 70° C. range. In this manner the effective necrosed volume can be determined.

It should be appreciated that in accordance with various aspects of the present invention, both echo time shifts and amplitude changes may be employed. For example, by scanning the windowed region in one, two, or three dimensions, a temperature map or image can be obtained.

Of course this technique may also be performed on an incremental basis to compensate for changes in temperature along some line, including, for example, before/after the hot 25 spot. For example, by windowing out regions from the transducer to the region of interest and in each region computing the temperature from attenuation techniques or phase shifts, a temperature profile can be accurately determined.

With reference to FIG. **6**, a temperature monitoring subsystem **400** which is interfaced to the acoustic transducer assembly **100** and monitor **500** is described below. The temperature monitoring subsystem **400** connected to the acoustic transducer assembly **100** via a cable **410** includes a control unit. The unit is operated so that the temperature mapping 35 process as follows is properly conducted.

In particular, an acoustic pulse wave is first generated by a single transmitting element 110 among the linear array of the acoustic transducer assembly 100. The thus generated acoustic pulse wave propagates into the target tissue 800 and 40 through any temperature gradients. Since the speed of sound in the target tissue 800 exhibits temperature dependency, the acoustic wavefronts will be sped up or slowed down in certain regions based on the temperature gradients existing in the target tissue 800. Upon reaching a boundary 850 used for 45 reference the acoustic wavefronts are reflected thereon so that the reflected wavefronts, i.e., the echoes come back towards the acoustic transducer assembly 100, where they are detected by remaining elements 120 in the linear array. Upon the echoes returned from the target tissue **800** are detected by 50 the acoustic transducer assembly 100, a certain signal is sent to the temperature monitoring subsystem 400 in which the time-of-flight data of the detected echoes (i.e., the returned acoustic wavefronts) which is a period of time required from the emission of a certain acoustic pulse to the detection of the 55 corresponding echo (the reflected acoustic wave) is calculated. The above transmitting-and-detecting sequence is repeated for each unique transmitter-receiver combination to form a large data set.

Finally, using propagation path data, the obtained time-of-flight data is numerically converted into speed data of sound in the target tissue, and then further into a matrix of temperature values. Specifically, the speed V of sound (in this case, the speed of the ultrasonic wave) in the target tissue is expressed as follows:

65

$$V = V_O + f(T) \tag{1}$$

10

where Vo represents the speed of sound at a certain temperature in the target tissue, T is a temperature of the target tissue, and f(T) is a function of T. Furthermore, the speed V of sound is also expressed as follows:

$$V=L/t$$
 (2)

where L represents the length of the propagation path while t represents the propagation time (i.e., the time of flight) which is required thr the sound (i.e., the acoustic wave) to cover the propagation path of the length L.

As a result, from the above-mentioned expressions (1) and (2), the temperature T of the target tissue can be calculated based on the measured time-of-flight (the propagation time) data t with using values for L, Vo and f(T). Typical values for Vo and f(T) are known in the art or readily measured in experiments. On the other hand, the propagation path length L for the above calculation can be determined in several manners.

For example, a small biopsy needle, typically metallic, with a square cross-section can be placed in the target tissue until reaching a predetermined depth. Such a metallic needle provides a large amount of reflection of the acoustic waves, thereby functioning an artificial reference boundary placed at the predetermined known depth in the target tissue.

Alternatively, instead of providing the artificial boundary, any natural boundaries existing in the target tissue can be used as the reference boundary which provides the basis of calculating the propagation path length. Such natural boundary will include a tissue-to-air boundary, a tissue-to-water boundary, a tissue-to-bone boundary, and the like.

When any actual artificial or natural boundaries are not available in the target tissue as the reference boundary, an imaginary boundary or a virtual boundary can be produced. When one acoustic pulse or wave is emitted toward the target tissue at a time of zero (0) and the corresponding returning echo is detected at a time of X, then the specific pulse or wave has traveled in the target tissue over a distance which is approximately calculated as X times the speed of sound. Thus, the signal processing and analysis in the subsequent processes can be conducted based on this particular echo as the reference.

Analogous to the time-of-flight data, and use thereof as described herein, in accordance with various aspects of the present invention, the amplitude of the returned echos can also be used to create an image of the acoustic attenuation.

The obtained temperature data is sent to the video display terminal 500 for visualization by the user, and also sent to the therapy subsystem 300 previously described for dynamic control of the heating process for the therapeutic treatment purposes.

In accordance with yet another embodiment of the present invention, temperature can be monitored using a tomographic approach (in addition to FIG. 6 embodiment). With reference to FIG. 7 the intersecting path of a transducer 100 having multiple elements is illustrated. The path of propagation is determined by the diffraction of the source and the properties of the medium. Along a path s the acoustic time-of-flight, T will be the integral of the incremental delays over s

$$T = \int \frac{ds}{\nu(s)} \tag{3}$$

65 It should be appreciated that the acoustic propagation will consist of phase retardation (additional delay) and diffraction loss (amplitude loss), refraction, and various tissues with

associated speed of sound characteristics, and each of these factors can, if desired, be included in the analysis.

In any event, by considering the intersecting paths, such as shown in FIG. 7, superimposed over a grid of pixels, where each pixel represents an area (volume) a tomographic configuration shown in FIG. 8 is obtained. By tracing the propagation and reception of the rays a solution to the velocity in each pixel from the matrix can be calculated according to the following equation:

$$[T] = [ds][1/v] \tag{4}$$

where [T] is a vector of measured delays, [ds] a matrix of known distances and [1/v] a vector of slowness, the reciprocal of the speed of sound (and thus temperature) in each pixel. Given the dependence of the speed of sound in tissue with 15 temperature, the spatial temperature distribution in each pixel is thus determined.

As noted briefly above, other factors including acoustic diffraction (beam spreading) and the temperature coefficients of tissue can be incorporated to enhance the accuracy of this 20 method. In accordance with a particularly preferred aspect, as will be described in more detail below, the array can be rotated to allow for a three-dimensional imaging as well as a map of temperature to be measured.

By measuring the ray paths and then heating the region and 25 rapidly re-measuring an accurate spatial map of heating is obtainable, such map being substantially free of tissue motion artifacts.

As described above, the ultrasonic therapy system of the present invention includes an acoustic transducer assembly (in other words, the acoustic transducer subsystem), a therapy subsystem (in other words, a therapeutic heating subsystem), and a temperature monitoring subsystem as well as an appropriate display and control interface. This architecture noninvasively provides essential functions of real-time imaging 35 and temperature monitoring of the treatment region during the therapeutic treatment process. This enables the user to obtain the feedback of the results of the therapeutic treatment process, resulting in improved, control of the process. By using the disclosed system of the present invention, safe, 40 automated, and well-controlled procedures for the therapeutic treatment process are achieved, at low cost and in only seconds or minutes of therapy. The use of the disclosed transducer capable of imaging, therapy, and monitoring allows precise geometric placement and monitoring of lesions, 45 which has not previously been possible with prior art systems and/or methodologies.

With reference to FIGS. **9**A-D and **10**A-B, the performance of a transducer made in accordance with the present invention will now be described. Specifically, a 5×5 mm 50 therapy transducer has been constructed in accordance with the present invention and the characteristics of that transducer determined.

With respect to FIG. **9**A, for example, the power versus frequency plot shown therein shows the electrical input, 55 acoustical output and heat loss curves, respectively. As will be appreciated, each of these aspects are well within desirable ranges. Similarly, and with reference now to FIG. **9**B, the transmit efficiency of the transducer over the range of 3-4 MHZ is on the order of above 80%, which, as will be appreciated by those skilled in the art, is more than acceptable. It should be appreciated that any suitable frequency range could be utilized.

Referring now to FIG. 9C, the voltage, current and impedance magnitude of the transducer over a similar frequency range (e.g., 3-4 MHZ) is shown. In accordance with this particular embodiment, the drive voltage is on the order of

12

about 30 volts, the current on the order of about 400 milliamps, and the impedance magnitude on the order of about 70 ohms.

Finally, with respect to FIG. **9**D, the acoustical power at high power outputs is shown, and, as such, it can be seen that as electrical power is increased, the heating efficiency drops. However, over acceptable ranges, transducers made in accordance with the present invention exhibit acceptable performance.

Referring now to FIG. 10, the pulse echo waveform of the aforementioned exemplary transducer is shown in FIG. 10A and the frequency spectrum of the echo, without electrical tuning, is shown in FIG. 10B. As will be appreciated by those skilled in the art, the frequency spectrum and echo voltage plots evidence the usability and functioning of transducers made in accordance with the present invention. Specifically, it will be noted that the transducers exhibit high fractional bandwidth. Although the specific transducer used in gathering the data shown in FIG. 10 comprises a transducer with a single matching layer and no electrical tuning, providing two or more matching layers, as noted above, and electrically tuning the transducer may enhance such characteristics to over 50% or more.

As discussed above, a need exists for the rapeutic ultrasonic systems to further provide enhanced imaging and treatment capabilities, such as three-dimensional imaging and temperature information, and three-dimensional therapeutic heating. In that regard, a combined imaging, therapy and temperature monitoring system comprising a single acoustic transducer 100 can be configured to provide a three-dimensional system and thus facilitate enhanced imaging and treatment capabilities. In accordance with this aspect, the three-dimensional system can provide volumetric information relating to the target tissue 800. By facilitating three-dimensional imaging and temperature monitoring of the target tissue 800, the threedimensional system enables medical practitioners to more readily ascertain the location, as well as the depth, of the treatment region. Accordingly, with the enhanced imaging and temperature monitoring of the treated region, therapeutic heating can be concentrated within a more specific area of the target tissue 800, thus resulting in improved therapeutic results.

Continuing in accordance with this aspect of the invention, the three-dimensional imaging, therapy and temperature monitoring system can be configured in various manners depending upon the particular application as well as various cost considerations. For example, the three-dimensional system can comprise a single acoustic transducer 100 configured to provide only three-dimensional imaging, three-dimensional mapping of temperature, or three-dimensional therapeutic heating of the treatment region. Further, the threedimensional system can be suitably configured to provide both three-dimensional imaging and three-dimensional temperature mapping, or may include either feature with threedimensional therapeutic heating. In accordance with a preferred aspect of the invention, the single acoustic transducer 100 is configured to provide all three features, i.e., threedimensional imaging, therapy and temperature monitoring.

In accordance with another aspect of the invention, the single transducer 100 can be suitably diced to form a 1-dimensional array, such as is described above.

Additionally, the single transducer 100 can be suitably diced in two-dimensions to form a two-dimensional array. For example, with reference to FIG. 14, an exemplary two-dimensional array 1400 can be suitably diced into two-dimensional portions 1402. The two dimensional portions 1402 can be suitably configured to focus on the treatment region at

a certain depth, and thus provide respective slices 1404 of the treatment region. As a result, the two-dimensional array 1400 can provide a two-dimensional slicing of the image plane of a treatment region 1406.

To provide three-dimensional imaging, temperature monitoring and therapeutic heating of the target tissue **800**, the three-dimensional system can comprise a single acoustic transducer **100** configured with an adaptive, algorithm, such as, for example, three-dimensional graphic software, contained in a control subsystem, such as, for example, the imaging subsystem **200**, the therapeutic subsystem **300** or the temperature monitoring subsystem **400**. The adaptive algorithm is suitably configured to receive two-dimensional imaging and temperature information relating to the region-of-interest, process the received information, and then provide corresponding three-dimensional imaging and temperature information.

In accordance with this aspect of the invention, the three-dimensional system suitably comprises a two-dimensional array 1400 to provide two-dimensional information to the 20 control subsystem. Accordingly, the adaptive algorithm may suitably receive slices 1404 from different image planes of the treatment region, process the received information, and then provide volumetric information 1406, e.g., three-dimensional imaging and temperature information. Moreover, after processing the received information with the adaptive algorithm, the two-dimensional array 1400 may suitably provide therapeutic heating to the volumetric region 1406 as desired.

Alternatively, rather than utilizing an adaptive algorithm, such as three-dimensional software, to provide three-dimensional imaging or temperature information, the three-dimensional system can comprise a single transducer 100 configured to operate from various rotational positions relative to the target tissue 800. In accordance with this aspect of the invention, the single transducer 100 may be suitably config- 35 ured in a one-dimensional array or a two-dimensional array, such as array 1400. For example, with reference to FIG. 11, the single transducer 100 can be configured to rotate around a perimeter 1104 of the treatment region to provide three-dimensional imaging and temperature information. Moreover, 40 the single transducer 100 can be configured to rotate around an axis 1102 to provide three-dimensional information. Still further, the single transducer 100 can be configured to translate or sweep along an axis 1103 to provide a larger field-ofview and thus facilitate additional three-dimensional infor- 45 mation. The rotational movement can comprise movement in either a clockwise or counterclockwise direction, or both. Further, the rotational movement could include complete or partial rotations. Thus, the rotational movement could include movement between only two positions, or between any other 50 number of rotational positions. Accordingly, the three-dimensional system 1100 may comprise a single transducer having any rotational and/or translational arrangement suitably configured to provide three-dimensional information.

Moreover, the movement of the single acoustic transducer 55 100 in various rotational and/or translational positions can be controlled by any mechanical scanning device now known or hereinafter devised for automated movement.

However, the rotational movement of the single acoustic transducer 100 may also be controlled by manually placing 60 the acoustic transducer 100 in various desired, rotational positions.

Still further, while the three-dimensional system may include a single acoustic transducer configured with a two-dimensional array 1400 and an adaptive algorithm to provide 65 three-dimensional imaging, temperature monitoring and therapeutic heating to a treatment region 1406, the three-

14

dimensional system may be configured to include both an adaptive algorithm and rotational and/or translational movement to provide additional information. As such, an even larger area of treatment may be obtained through the use of both the adaptive algorithm and the rotational and/or translational movement.

Continuing with this example, the three-dimensional system can be suitably configured to capture imaging and temperature information and provide therapeutic heating from the acoustic transducer 100 once the transducer 100 becomes fixedly maintained at various rotational positions. Further, the three-dimensional system can also be suitably configured to capture imaging and temperature information and provide therapeutic heating just prior to, or just after, becoming fixedly positioned. Moreover, the three-dimensional system can be configured to capture imaging and temperature information and provide therapeutic heating during movement around the various rotational positions.

Having obtained imaging and temperature information corresponding to a three-dimensional representation of the treatment region within the target tissue 800, whether through the use of an adaptive algorithm, such as three-dimensional software, rotational movement of the acoustic transducer, or both, improved the rapeutic treatment can be facilitated by the imaging, therapy and temperature monitoring system 1100. Moreover, imaging and temperature information can be accumulated to provide three-dimensional representation of the image and temperature within the treatment region which enables the system 1100 to more readily ascertain the location and depth, as well as temperature of the region-of-interest. Still further, based on the three-dimensional information, the system 1100 can be suitably automated if desired to provide therapeutic treatment to a selected volume within the regionof-interest.

In accordance with another embodiment of an ultrasonic system for providing therapeutic treatment, a single ultrasonic probe may be provided which includes at least two acoustic transducers configured within the probe. In accordance with this exemplary embodiment, at least one of the acoustic transducers is configured to facilitate imaging, temperature monitoring and therapeutic heating for a treatment region. With reference to FIG. 12, an exemplary embodiment of such an ultrasonic system 1200 is shown.

In accordance with this exemplary embodiment, the ultrasonic system 1200 suitably comprises a single probe 1202 having at least two acoustic transducers 1204 and 1206. The single probe 1202 comprises any conventional probe configured for having multiple transducers within. In the exemplary embodiment, the probe 1202 comprises a cylindrical endoscope. However, the probe 1202 may also comprise a catheter or a cystoscope and the like. Additionally, as will be described in more detail below, the single probe 1202 may be rotatably connected to the ultrasonic system 1200 to permit rotational movement of the acoustic transducers 1204 and 1206. Moreover, although only two acoustic transducers 1204 and 1206 are shown, the single probe 1202 may suitably include any number of acoustic transducers.

The acoustic transducers 1204 and 1206 are suitably configured within the probe 1202 to provide imaging, temperature monitoring and therapeutic treatment of the treatment region. Notably, at least one of transducers 1204 and 1206 comprises a single transducer 100 for providing imaging, temperature monitoring and therapeutic heating, at least one of transducers 1204 and 1206 can facilitate all three functions, imaging, temperature monitoring and therapeutic heating. Moreover, each transducer 1204 and 1206 may separately provide imaging, temperature monitoring and

therapeutic heating. In addition, transducers 1204 and 1206 may be configured with various ranges of operating, frequency, such as, for example, between 1 to 18 MHZ or more.

In accordance with another aspect of the invention, transducers 1204 and 1206 are suitably configured in different 5 positional orientations within probe 1202. In accordance with the exemplary embodiment, the transducers 1204 and 1206 are suitably configured in substantially opposing directions. Accordingly, transducers 1204 and 1206 can provide respective fields-of-view (image or treatment planes) 1208 and 1210 10 which represent separate regions-of-interest. Moreover, by rotating probe 1202, for example, such as by rotational movement 1212, each transducer 1204 and 1206 can provide either field-of-view 1208 or 1210, or various fields-of-view in

Although the fields-of-view 1208 and 1210 are shown as separate regions-of-interest, the transducers 1204 and 1206 may also be suitably positioned within the probe 1202 such that the fields-of-view 1208 and 1210 suitably overlap. Accordingly, the ultrasonic probe 1202 of the exemplary 20 embodiment can suitably provide simultaneous operation within two regions-of-interest, or can provide sequential operations within the same region-of-interest. Moreover, as a result of the above rotational configurations, three-dimenreadily obtained. Still further, by operating transducers 1204 and 1206 simultaneously, the imaging, temperature monitoring, and therapeutic heating can be suitably provided over a larger area of the target tissue if desired.

In accordance with another aspect of this exemplary 30 embodiment, the transducers 1202 and 1204 may be suitably configured with different operating frequencies. Thus, transducer 1202 may be configured for high frequency imaging, for example, between 12 to 18 MHZ, while transducer 1204 may be configured for low frequency imaging, for example, 35 between 3 to 5 MHZ. Moreover, transducer 1202 may be configured for low frequency imaging while transducer 1204 is configured for high frequency imaging. By having such different frequencies, particularly if operating simultaneously, transducers 1202 and 1204 can suitably provide 40 capabilities of both high frequency, which facilitates high resolution imaging, and low frequency, which easily controls beamwidth and depth of penetration. Accordingly, an ultrasonic probe can be realized which provides a wider range of imaging information.

In accordance with another embodiment of an ultrasonic system for providing therapeutic treatment, an extracorporeal probe, for example, one outside the body, having at least one acoustic transducer may be included with an endoscopic or cystoscopic probe and the like, for example, one proximate to 50 the target tissue, also having at least one acoustic transducer. Further, both probes are suitably oriented such that the respective transducers are configured to operate on substantially the same treatment region. As a result, therapeutic heating can be focused towards the treatment region in a manner 55 that provides increased intensity. In accordance with this exemplary embodiment, at least one of the acoustic transducers is configured to facilitate imaging, temperature monitoring and therapeutic heating for a treatment region. With reference to FIG. 13, an exemplary embodiment of such an 60 ultrasonic system 1300 is shown.

In accordance with this exemplary embodiment, the ultrasonic system 1300 suitably comprises a extracorporeal probe 1302 and an endoscopic probe 1304.

The extracorporeal probe 1302 suitably comprises any 65 conventional, probe configured for external or non-invasive use. Accordingly, the single extracorporeal probe 1302 is

16

suitably configured outside a body region 1312, for example, proximate a bodily surface 1310. Meanwhile, the single endoscopic probe 1304 suitably comprises any conventional probe, such as, for example, endoscopic, cystoscopic, or catheter-based probe and the like, configured for invasive use proximate to a target tissue 800. Accordingly, the single endoscopic probe 1304 is suitably configured within a body region 1312 and proximate the target tissue 800. Moreover, although only a single acoustic transducer 1306 and 1308 are respectively shown for the probes 1302 and 1304, any number of acoustic transducers may be included within the probes 1302 and 1304.

The acoustic transducers 1306 and 1308 are suitably configured within the probes 1302 and 1304, respectively, to provide imaging, temperature monitoring and therapeutic treatment of the treatment region. Notably, at least one of transducers 1306 and 1308 comprises a single transducer 100 for providing imaging, temperature monitoring and therapeutic heating. Moreover, each transducer 1306 and 1308 may separately provide imaging, temperature monitoring and therapeutic heating. In addition, transducers 1306 and 1308 may be configured with various ranges of operating frequency, such as, for example, between 1 to 18 MHz or more. As a result, the ultrasonic system 1300 can obtain multiple sional imaging and temperature information can also be 25 amounts of information from probes 1302 and 1304 regarding the imaging and temperature monitoring of a desired treatment region within the target tissue 800, while also providing an increase in the intensity of the therapeutic treatment of the treatment region.

> The present invention has been described above with reference to various exemplary embodiments. However, those skilled in the art will recognize that changes and modifications may be made to the exemplary embodiments without departing from the scope of the present invention. For example, the various transducers, probes and other components may be implemented in alternate ways, or may be comprised of different materials and thicknesses, depending upon the particular application or in consideration of any number of performance criteria associated with the operation of the system. Further, the number of transducers and probes configured within the various exemplary embodiments is not limited to those described herein. In addition, the techniques described herein may be extended or modified for use with other modes of ultrasonic therapy in addition to the therapeutic heating system of the exemplary embodiments. These and other changes or modifications are intended to be included within the scope of the present invention, as expressed in the following claims.

The invention claimed is:

- 1. A method for the rapeutic treatment comprising the steps
 - providing an ultrasonic therapy system comprising a single ultrasound transducer, a display, and a control interface;
 - operating the control interface to control the single ultrasound transducer to non-invasively provide imaging of a targeted tissue below a skin surface, provide temperature monitoring of the targeted tissue, and provide therapeutic heating of the targeted tissue, such that the imaging, the temperature monitoring, and the therapeutic heating are conducted through the use of the single ultrasound transducer.
- 2. The method according to claim 1, further comprising providing feedback from the temperature monitoring temperature of the targeted tissue, and controlling the therapeutic heating of the targeted tissue based on the feedback.

- 3. The method according to claim 1, further comprising moving the single ultrasound transducer along the skin surface to provide an increased amount of the target tissue.
- **4.** The method according to claim **3**, further comprising providing the imaging, the temperature monitoring, and the 5 therapeutic heating of the increased amount of the target tissue.
- **5**. The method according to claim **1**, wherein the imaging of a targeted tissue below a skin surface provides a three-dimensional image of at least a portion of the targeted tissue. 10
- **6**. The method according to claim **1**, further comprising moving the single ultrasound transducer to form an increased amount of the target tissue, and damaging the increased amount of the target tissue.
- 7. The method according to claim 1, wherein the single 15 ultrasound transducer provides a center frequency in a range from 500 kHz to 20 MHZ.

* * * * *



专利名称(译)	成像,治疗和温度监测超声波方法		
公开(公告)号	<u>US9272162</u>	公开(公告)日	2016-03-01
申请号	US13/937190	申请日	2013-07-08
申请(专利权)人(译)	引导治疗系统有限责任公司		
当前申请(专利权)人(译)	引导治疗系统公司		
[标]发明人	SLAYTON MICHAEL H BARTHE PETER G		
发明人	SLAYTON, MICHAEL, H. BARTHE, PETER, G.		
IPC分类号	A61B8/00 A61N7/02 A61B5/01 A6	1B8/08 A61B5/00 A61B8/15 A	61B17/22
CPC分类号	A61B5/01 A61B8/0833 A61B8/522 G16H50/30	3 A61N7/02 A61B5/015 A61B	5/4836 A61B8/15 A61B2017/22028
优先权	11/744655 2013-07-09 US 10/193419 2007-06-12 US 08/950353 2000-04-18 US 09/502174 2002-12-31 US		
其他公开文献	US20130296697A1		
外部链接	Espacenet USPTO		

摘要(译)

用于提供成像,治疗和温度监测的超声系统通常包括声换能器组件,其被配置为使超声系统能够执行成像,治疗和温度监测功能。声换能器组件包括单个换能器,其可操作地连接到成像子系统,治疗子系统和温度监测子系统。超声系统还可以包括用于成像和温度监测功能的显示器。另外,声换能器组件可以配置成通过使用自适应算法和/或旋转或平移运动来提供三维成像,温度监测或治疗加热。而且,可以提供多个示例性单个换能器以促进增强的治疗能力。

